PSCC's institutional partners
The PSCC is at the heart of a first-in-class ecosystem that brings together academic and industrial experts from a wide range of disciplines, technologies, organizations and institutions.
The PSCC acts as a catalyst for transforming potentially revolutionary approaches into industrial diagnostic and therapeutic solutions for the fight against cancer.
The cluster is formalizing some of its partnerships, in particular with players who, like the PSCC, have a cross-functional mission to support companies and projects. These partnerships are set to expand, for the benefit of innovation and patients alike.
Current Partnerships
EIT Health is a European network of healthcare investors supported by the European Union. Our partnership with EIT Health provides PSCC projects with privileged access to European investors, as well as training and support.
Recognised as a charity, the ARC Foundation for Cancer Research is 100% dedicated to cancer research and is funded by the generosity of its donors and benefactors. In 2024, it allocated nearly €33 million to 332 research projects offering hope to patients. For the ARC Foundation, everything stems from a firm belief: research will defeat cancer. It is thanks to the discoveries made by researchers that we will ultimately emerge victorious: one day finding a cure for cancer, for all cancers.
.png)
Future4care is a European ecosystem of multidisciplinary stakeholders dedicated to digital health. A joint venture founded in 2021 by an alliance of Capgemini, Generali, Orange and Sanofi, Future4care brings together players in the digital health sector (major groups, experts, healthcare professionals, start-ups, etc.) to create synergies and opportunities that will accelerate progress in the field of digital health. Since its launch, Future4care has brought together industrial and institutional partners (Be-ys, Biocodex, Elior, Havas Life, TNP, Elior, UCB and FEHAP) and qualified figures from scientific and academic circles within a Scientific and Ethics Council.
Awarded the Carnot label in 2020, the OPALE Carnot Institute is a preferred partner of healthcare manufacturers for the research and development of innovative solutions for the diagnosis, treatment, and monitoring of patients suffering from leukemia and related diseases, together the most deadly blood cancer and the leading childhood cancer. With approximately 500 researchers, clinicians, and operational staff spread across 27 entities led by scientific opinion leaders and supported by leading regulatory authorities (INSERM, CNRS, CEA, EFS, AP-HP, Université Paris-Cité, etc.), OPALE offers manufacturers unique access to the expertise and resources of a consortium with no international equivalent in the field.
CALYM is a consortium of twenty entities specializing in lymphoid disease research that offer a comprehensive range of support in the clinical research and development of therapeutic solutions, within a rapidly expanding global pharmaceutical and biotechnology market. In response to the strategic evolution of the sector, which increasingly requires biological, clinical, and technological expertise from academia, CALYM stands out through its unique positioning. Its expertise covers the entire R&D value chain, from the identification of new cellular targets to international phase III clinical trials and beyond.
As part of the Deep Tech Centre at HEC Paris’s Institute of Innovation & Entrepreneurship, HEC Challenge+ supports researchers and founders of innovative, high-growth projects through a unique combination of training, expert advice and tailored support. Backed by a diverse network, it has established itself as a pioneering leader in the field of entrepreneurial education. A true pioneer in training innovative entrepreneurs, HEC Challenge+ has also expanded to Abidjan and Dakar, and has now established itself as the undisputed leader in its market.
ITCC is a European academic network of experts in pediatric oncology. The objective of the partnership with the PSCC is to encourage and support the development of solutions targeting pediatric cancers. To support innovation, ITCC offers expertise (design of pediatric development plans, preparation of clinical trials, etc.) and, via ITCC P4, a preclinical proof-of-concept platform in pediatric oncology (PDX models). ITCC is leading the PSCC Pediatrics working group alongside Sanofi.
Matwin, a subsidiary of Unicancer, is a national player that aims to develop entrepreneurship in oncology through partnering events, including Meet2Win, and a project acceleration program, submitted to an international board composed of industrial decision-makers in oncology and academic opinion leaders in the sector. The PSCC enriches Matwin's offering by providing projects selected in its program with part of its support offer. In addition, they work together to drive the OncoStart training program.
Medicen is the healthcare competitiveness cluster in the Île-de-France region. Our partnership is embodied in particular by joint membership in Medicen and PSCC Connect. Together, the PSCC and Medicen contribute to the ecosystem and exchange expertise for the benefit of projects, for example, regarding access to non-dilutive financing.
OncoSTART is a collective that encourages and energizes French entrepreneurship in the fight against cancer. OncoSTART's members are the cancer research centers, the Carnot Institutes, Gustave Roussy Transfert, Matwin, Unicancer, LSLead, and, since 2022, the PSCC. Together, these stakeholders implement initiatives to promote entrepreneurship, including awareness days, training sessions, and events.
Resah is a public interest group (GIP) whose aim is to support the pooling and professionalisation of procurement within the public and private non-profit healthcare sector. Established in 2007 to support the pooling of hospital procurement for the Île-de-France region, Resah opened up access to its contracts nationwide in 2016 at the request of the DGOS. It has thus become one of the sector’s leading operators.
.png)
Quest for Health is the Grand Est region’s incubator dedicated to healthcare start-ups at European level. Launched on the initiative of the Quest for Change incubator network (based in Reims, Strasbourg, Metz, Charleville-Mézières, Épinal and Mulhouse), the incubator supports more than sixty biotech, medtech and e-health start-ups. Quest for Health positions itself as the leading player in this field at national level. Among the start-ups supported, 21 are winners of the national i-Lab competition (including four grand prizes), five of the i-Nov competition and two of the EIC Accelerator. In 2021, they raised a total of €55 million in funding based on agreed valuations of €190 million. Quest for Health aims to foster healthcare innovation in the Grand Est region as well as internationally. With the support of its German and Swiss partners, the incubator guides entrepreneurs as swiftly as possible towards key milestones in their project’s development through pragmatic, supportive and impartial mentoring, led by a team of experts comprising mainly entrepreneurs. Launched in December 2022, the incubator is based at Nextmed, the medical technology campus in Strasbourg.